Wedbush analyst Laura Chico raised the firm’s price target on Maze Therapeutics (MAZE) to $58 from $43 and keeps an Outperform rating on the shares. The firm is revisiting its MZE782 pricing assumptions as PKU competitors continue to show strong uptake of newer agents, and this reinforces its view on the need for novel PKU treatments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
- Maze Therapeutics initiated with an Outperform at Mizuho
- Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
- Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
- Maze Therapeutics price target raised to $58 from $46 at Guggenheim